StockData
Cellectar Biosciences, Inc. logo

Cellectar Biosciences, Inc. (CLRB) stock

CLRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$0.89−0.04 (-3.81%)

Close on Nov 18, 2026Market cap $8.37MP/E –Yield –

Cellectar Biosciences free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Cellectar Biosciences's free cash flow for the twelve months ending Dec 31, 2024 was -$47.69M. For fiscal 2025 it was -$23.12M. The highest annual figure on record is -$3.38M in fiscal 2010.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$23.12M–
FY2024Dec 31, 2024-$47.69M–
FY2023Dec 31, 2023-$33.24M–
FY2022Dec 31, 2022-$25.45M–
FY2021Dec 31, 2021-$22.71M–
FY2020Dec 31, 2020-$14.00M–
FY2019Dec 31, 2019-$11.72M–
FY2018Dec 31, 2018-$11.83M–
FY2017Dec 31, 2017-$11.37M–
FY2016Dec 31, 2016-$8.35M–
FY2015Dec 31, 2015-$8.27M–
FY2014Dec 31, 2014-$8.87M–
FY2013Dec 31, 2013-$9.30M–
FY2012Dec 31, 2012-$6.68M–
FY2011Dec 31, 2011-$6.09M–
FY2010Dec 31, 2010-$3.38M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$6.01M–
Q1 FY2026Mar 31, 2026-$4.85M–
Q4 FY2024Dec 31, 2024-$10.97M–
Q3 FY2024Sep 30, 2024-$9.17M–
Q2 FY2024Jun 30, 2024-$14.16M–
Q1 FY2024Mar 31, 2024-$13.38M–
Q4 FY2023Dec 31, 2023-$9.86M–
Q4 FY2022Dec 31, 2022-$7.53M–
Q3 FY2022Sep 30, 2022-$7.02M–
Q2 FY2022Jun 30, 2022-$5.83M–
Q1 FY2022Mar 31, 2022-$5.07M–
Q4 FY2021Dec 31, 2021-$4.64M–
Q3 FY2021Sep 30, 2021-$6.43M–
Q4 FY2020Dec 31, 2020-$3.89M–
Q3 FY2020Sep 30, 2020-$3.50M–
Q2 FY2020Jun 30, 2020-$3.08M–
Q1 FY2020Mar 31, 2020-$3.52M–
Q4 FY2019Dec 31, 2019-$2.69M–
Q3 FY2019Sep 30, 2019-$3.55M–
Q2 FY2019Jun 30, 2019-$2.66M–
Q1 FY2019Mar 31, 2019-$2.82M–
Q4 FY2018Dec 31, 2018-$3.13M–
Q3 FY2018Sep 30, 2018-$2.97M–
Q2 FY2018Jun 30, 2018-$2.55M–
Q1 FY2018Mar 31, 2018-$3.19M–
Q4 FY2017Dec 31, 2017-$2.83M–
Q3 FY2017Sep 30, 2017-$2.57M–
Q2 FY2017Jun 30, 2017-$2.92M–
Q1 FY2017Mar 31, 2017-$3.05M–
Q4 FY2016Dec 31, 2016-$2.42M–
Q3 FY2016Sep 30, 2016-$2.21M–

More Cellectar Biosciences figures

See a number that looks wrong?